| Drug General Information |
| Drug ID |
D02LHR
|
| Former ID |
DNC003773
|
| Drug Name |
INDORAMIN
|
| Drug Type |
Small molecular drug
|
| Indication |
Hypertension [ICD9: 401; ICD10:I10-I16]
|
Withdrawn from market |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C22H25N3O
|
| InChI |
InChI=1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26)
|
| InChIKey |
JXZZEXZZKAWDSP-UHFFFAOYSA-N
|
| CAS Number |
CAS 26844-12-2
|
| PubChem Compound ID |
|
| PubChem Substance ID |
3145511, 4954321, 7979608, 8173213, 11393053, 14778365, 26534678, 29217568, 34675413, 47206378, 47227712, 47301929, 47451424, 47747528, 47971029, 48345790, 49671666, 49876989, 50603739, 57311546, 85209952, 89765137, 92270335, 103006849, 103194521, 103941454, 104316511, 117564550, 124638943, 125163373, 125433253, 128343844, 134224549, 134340978, 134997857, 135650391, 136050062, 137248543, 141645446, 152133947, 162185578, 179150251, 184547504, 187071875, 198950576, 223519058, 224810415, 226433258, 226433259, 241046546
|
| SuperDrug ATC ID |
C02CA02
|
| Target and Pathway |
| Target(s) |
Alpha-1D adrenergic receptor |
Target Info |
Inhibitor |
[3]
|
|---|
| Alpha-2C adrenergic receptor |
Target Info |
Inhibitor |
[3]
|
| Alpha-2B adrenergic receptor |
Target Info |
Inhibitor |
[3]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Salivary secretionhsa04022:cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04022:cGMP-PKG signaling pathway
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Reactome
|
Adrenoceptors
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling eventsR-HSA-390696:Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling events
|
|
Surfactant metabolismR-HSA-390696:Adrenoceptors
|
|
WikiPathways
|
Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP58:Monoamine GPCRs
|
|
Platelet Aggregation (Plug Formation)
|
|
Integration of energy metabolism
|
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 501). |
|---|
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
|---|
| REF 3 | J Med Chem. 1995 Sep 1;38(18):3415-44.Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
|---|
